ADVENTRX Pharmaceuticals Inc. Presents At The 12th Annual Bio CEO & Investors Conference Today:

ANX is one of my favorite small cap BioTech stocks at the moment.

It is listed on the AMEX exchange, and is currently trading at around $0.30 per share. It has been a Volume Leader on the AMEX for two months or so. Here is a link to the company's website:

http://www.adventrx.com/

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens.

ADVENTRX is presenting at the 12th Annual Biotechnology Industry Organization CEO & Investor Conference. Here is a list of all of the companies presenting at the conference. I have been following many of them for over a year:

http://ceo.bio.org/opencms/ceo/2010/Companies/PresentingCompanies.html

Here is the link to listen to the webcast live at 10:30am ET, or you can listen to it later:

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-IRHome

I don't expect any new news to be presented at this conference, because SEC Regulations require that a press release of any material event must be published to the entire world and not just to the participants of a conference.

But they may surprise us on this, because some types of developments don't require a press release. The best news they could give us today would be to name a target date for submitting a new drug application (NDA) for the second drug in their pipeline ANX-514.

There have also been buy out rumors spread all over the internet about this company over the past two months, but I don't think this has a possibility of happening until after the FDA approves the NDA for their first drug candidate ANX-530. ANX submitted a NDA to the FDA for this drug the last week of December 2009, and the FDA has sixty days to rule if they will accept or decline this NDA or not. We should hear news on this during the last week of February, or during the first week of March.

There are also talks of partnerships with one or more of the big BioTech companies. One of the purposes of a conference like today's is to have private meetings with the CEO's of the presenting companies. News of either a buy out or a partnership would surely be good news for this company, and it should reflect well on their share price.

I will be watching for unusual volume and price action on ANX today and the rest of this week. I will post my thoughts about their presentation later today. ANX is one of the few stocks that I am an "investor" in. I also have another block of shares that I trade in and out with using my day trading account.

Happy Trading,
zigzagman